In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical ...

Learn how IVIG works to treat and manage HDFN, as well as other treatments that may improve an HDFN-affected infant's ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Medically reviewed by Corinne Savides Happel, MD The immune system is responsible for protecting the body from disease. And ...

GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Johnson & Johnson today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment ...

Learn more about how corticosteroids given before birth can improve outcomes for infants born prematurely, including those ...

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...

At Dyadic, we remain committed to leveraging our innovative C1 and Dapibus protein production platforms to address some of the most pressing ...

This autoimmune disease is tricky to diagnose because it mimics so many other illnesses. If you have more than four of any of ...

For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat ...